Association between antibiotic exposure and survival outcomes in hepatocellular carcinoma patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis
Oct 2026· PeerJ· Vol 14, pp. e21840· 0 citations· 53 references
Medicine
TL;DR
For HCC patients receiving ICI therapy, antibiotic exposure was significantly associated with reduced OS, and a significant association with poorer PFS was observed, although this finding was not robust in sensitivity analyses and should therefore be interpreted with caution.
Abstract
Objective Patients with hepatocellular carcinoma (HCC) treated with immune checkpoint inhibitors (ICIs) are frequently exposed to antibiotics. This study aims to evaluate the impact of antibiotic use on the survival outcomes of HCC patients treated with ICIs. Methods This study followed the PRISMA guidelines and systematically retrieved literature from PubMed, Embase, and Cochrane Library databases up to August 7, 2026. Studies comparing the clinical outcomes (overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR)) of HCC patients receiving ICI treatment with and without antibiotic exposure were included. The quality of the studies was assessed using the Newcastle-Ottawa Scale. Before conducting the meta-analysis, the original hazard ratios (HRs)/odd ratios (ORs) and their 95% CIs were log-transformed to achieve a normal distribution. Statistical analysis was performed using Stata 15 software, and pooled HRs/ORs with 95% CIs were calculated. Results A total of 12 retrospective cohort studies were included, involving 3,643 patients (761 exposed to antibiotics). The results showed that the median OS of the antibiotic-exposed group (12.2 months) was shorter than that of the non-exposed group (17.0 months). The meta-analysis indicated that antibiotic use was significantly associated with poorer OS (HR = 1.29, 95% CI [1.17–1.41]). Sensitivity analyses confirmed the robustness of the OS finding. In terms of PFS, the median PFS of the antibiotic-exposed group (5.2 months) was shorter than that of the non-exposed group (7.5 months), and antibiotic use was also significantly associated with poorer PFS (HR = 1.27, 95% CI [1.01–1.59]), although this association was not robust in sensitivity analyses. The analyses of ORR and DCR did not show significant differences between the groups. No significant publication bias was detected on the basis of visual inspection of funnel plots and Egger’s and Begg’s tests. Conclusion For HCC patients receiving ICI therapy, antibiotic exposure was significantly associated with reduced OS. A significant association with poorer PFS was also observed, although this finding was not robust in sensitivity analyses and should therefore be interpreted with caution. No statistically significant differences were observed for ORR or DCR.
INTRODUCTION
The prevalence of malnutrition in cancer patients is already high at diagnosis, reaching up to 40%, and tends to increase during treatment, affecting up to 75-80% of patients. To investigate the relationship between nutritional status and clinical outcomes, Progression-Free Survival (PFS) and Overall Survi...
Chiara Paciolla, E. Vitale, L. Maistrello et al.· Clinical Nutrition ESPEN· 0 citations
To comprehensively assess the association of pretreatment systemic immune-inflammation index (SII) with the prognosis of gastric cancer patients.
PubMed, Web of Science, Embase, and the Cochrane Library were searched to select studies exploring the association of SII with the overall survival (OS), progressi...
Zi-Yi Yu, Xue Liu, Guo-Liang Hu et al.· Frontiers in Oncology· 0 citations
The aim of this systematic review and meta-analysis was to estimate the pooled proportional incidence of tuberculosis (TB) in cancer patients treated with immune checkpoint inhibitors (ICIs).
PubMed, Embase, and the Cochrane Library were searched from inception through December 31, 2025.
Cohort and...
Po-Huang Chen, Min-Chi Cheng, Ming-Shen Dai et al.· Journal of Cancer Research a...· 0 citations
In patients with EC receiving ICIs, the occurrence of irAEs may be a prognostic marker of favorable outcomes, however, wide PIs for PFS and ORR indicate that these associations may vary across future studies and immortal time bias may overestimate survival associations.
Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, yet their efficacy and safety in patients with chronic kidney disease (CKD) remain uncertain, as this population is frequently excluded from pivotal trials. We aimed to evaluate clinical outcomes of ICI therapy in patients with cancer and CKD....
R. Pereira Silva, M. Lourenço Ferreira, Davi R. S. G. Amorim et al.· Journal of Onco-Nephrology· 0 citations
BACKGROUND AND AIMS
Interleukin-6 (IL-6) has been implicated in the pathogenesis of hepatocellular carcinoma (HCC) and resistance to systemic therapy. This study aimed to evaluate the prognostic value of circulating IL-6 in patients with HCC receiving systemic therapy through a systematic review and meta-analysis.
ME...
Y. Perfilyeva, N. Abdolla, A. Kali et al.· Future Oncology· 0 citations
Related blog posts
Microsoft Research Blog· microsoft.comNov 12, 2026
What's new in research at Microsoft? Host Anson Ho explores the latest, including AI-powered universal translation, a breakthrough in a 31-year-old mathematics challenge, and advances making AI coding agents faster and more efficient. The post Microsoft Research Focus – Edition #98 appeared first on Microsoft Research.
AI agents can generate code at a scale that’s hard for humans to review line-by-line. PDD Kit helps ensure the code is doing what the developer intended by creating formal specifications and testing against them. It converts developer intent into a Verus specification, proves AI-generated code meets it for every input, and uses tests where proofs aren't practical. Developers review intent, not every line. The post Formally verifying agent-written full-stack web apps with PDD Kit appeared first o…